Navigation Links
WuXi PharmaTech Announces Second-Quarter 2010 Results
Date:8/1/2010

Second-quarter 2010 GAAP net income declined 6% year over year to $13.8 million due to an unfavorable change in other income (expenses) net and higher taxes, offset by the 18% increase in operating income, which was impacted by $2.9 million of non-recurring deal costs relating to the previously proposed combination with Charles River Laboratories. In second-quarter 2009, other income (expenses) net included gains from settlement of escrow shares of $1.7 million associated with the AppTec acquisition. The year-over-year increase in tax expense was mainly driven by higher 2010 China statutory tax rates compared to 2009 as a result of the income tax transitional phase-out rules in China.

Second-quarter 2010 GAAP diluted earnings per ADS decreased 8% to 18 cents, mainly due to the 6% decrease in net income. Non-recurring deal costs associated with the terminated WuXi - Charles River merger had an impact of 4 cents per share.

Non-GAAP Results

Non-GAAP financial results excluded the impact of share-based compensation expenses, amortization of acquired intangible assets and the associated deferred tax impact, and non-recurring deal costs relating to the previously proposed combination with Charles River Laboratories.

Second-quarter 2010 non-GAAP gross profit increased 23% year over year to $35.0 million, due to strong contributions from both Laboratory Services and Manufacturing Services, driven by revenue growth and gross-margin improvement in both segments. Second-quarter 2010 non-GAAP gross margin improved year over year due to improved project mix in both Laboratory Services and Ma
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
2. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
3. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
4. WuXi PharmaTech Announces First-Quarter 2010 Results
5. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
6. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
7. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
8. WuXi PharmaTech Schedules Fourth-Quarter 2009 Earnings Release
9. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
10. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
11. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
... -16 April, is taking full advantage of its Geneva ... of the World Health Organisation (WHO), the World Heart ... the International Olympics Committee (IOC). On Thursday 14 ... (EACPR) will host joint sessions including a session looking ...
... With efforts underway to ban lead-based ammunition as a ... evidence that a prime alternative material for bullets ... report, which found that tungsten accumulates in major structures ... journal Chemical Research in Toxicology . Jose ...
... FL (April 6, 2011) Numerous studies show that ... cancer. However, animal studies testing the NSAID naproxen or ... formation. Now, researchers at Fox Chase Cancer Center find ... strain of mutant mice that spontaneously develop colon tumors. ...
... By Serena Gordon HealthDay Reporter , ... analysis from the Women,s Health Initiative (WHI) study, researchers ... estrogen-only hormone therapy faded rapidly after they ended the ... stopped taking estrogen, the risk of stroke and blood ...
... , WEDNESDAY, April 6 (HealthDay News) -- Compared ... to experience bleeding and infections during and after a ... analyzed data from 20,353 women who had a hysterectomy ... menstruation, benign muscle tumors and pain. Women with ...
... strawberries may be a way to help people at risk ... a new study by researchers at The Ohio State University ... Richard J. Solove Research Institute (OSUCCC James) and researchers ... during a press briefing at 8 a.m. April 6 at ...
Cached Medicine News:Health News:International organizations join forces to promote cardiovascular health 2Health News:International organizations join forces to promote cardiovascular health 3Health News:Fox Chase researchers report that naproxen reduces tumors in a mouse model of colon cancer 2Health News:Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends 2Health News:Risks of Estrogen Hormone Therapy Seen to Fade After Treatment Ends 3Health News:Weight Linked to Complications in Some Hysterectomy Patients 2Health News:An international study in China finds strawberries may slow precancerous growth in the esophagus 2Health News:An international study in China finds strawberries may slow precancerous growth in the esophagus 3
Iso-Electric Determination Kit; contains 1 bottle of 40 nm Naked Gold Iso-Electric Determination Kit to optimize gold conjugation of antibodies...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 12 OD...
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 50 OD...
Colloidal Gold Conjugated, Rabbit anti-goat IgG (H&L) - 12 OD...
Medicine Products: